Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Substanzprofil
Lysergsäurediethylamid (LSD-25) ist ein halbsynthetisches Ergolin-Derivat und eines der potentesten bekannten Psychedelika, aktiv bereits im Mikrogramm-Bereich. Es wurde 1938 von Albert Hofmann bei Sandoz in Basel erstmals synthetisiert und 1943 in seiner psychoaktiven Wirkung entdeckt. LSD bindet mit hoher Affinität an eine Vielzahl serotonerger und dopaminerger Rezeptoren und zeichnet sich durch seine aussergewöhnlich lange Wirkdauer von bis zu 12 Stunden aus. Die aktuelle Forschung untersucht LSD-assistierte Therapie bei Angststörungen, Cluster-Kopfschmerz und Alkoholabhängigkeit.
High-affinity serotonin 2A receptor agonist with unique binding kinetics
Partial agonism at D2 receptors contributing to stimulant effects
Profound DMN desynchronization enabling ego dissolution
Berichtete subjektive Effekte basierend auf klinischen und Community-Daten
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.
CBCT Assessment of Palatal Safe Zones in Adults with Various Skeletal Patterns.
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
Psychedelic therapy and cultural humility.
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis.
Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.
Alkaline Phosphatase and Infantile GM1 Gangliosidosis: A Simple Biomarker for a Complex Disease?
Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.
Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease.
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review.
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.
Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.
LSD: Mechanisms and relevance to the treatment of depression.
The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
Microdosing LSD in Women With Premenstrual Disorders
Between enhancement and risk: A critical review of psychedelic microdosing.
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers.
Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study.
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Human neuroimaging: fMRI.
Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?
Clinical pharmacology.
Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.
Psychedelics, entactogens and psychoplastogens for depression and related disorders.
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.
The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.
Acute Effects of the Psychedelic Phenethylamine 25I-NBOMe in C57BL/6J Male Mice.
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.
Psychedelic-assisted therapy: An overview for the internist.
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential.
Is there a place for psychedelics in sports practice?
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes.
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential.
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.
Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents.
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.